BioVie -22%. The shares of common stock and the tradable warrants may be transferred separately immediately upon issuance. (Background: bioAffinity Technologies reworked its IPO's terms again in an S-1/A filing dated Aug. 5, 2022: The number of units was increased to 1.29 million units (1,285,325 units) - up from 1.18 million units - and the assumed IPO price was raised to $6.125 per unit from $6.00. This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Elzi, P. Fatland, B. Karia, M. Iza, A Pertsemlidis, V.I. Total gross proceeds from the . The tests automated analysis of the flow cytometry data detects cell populations that indicate cancer is present. In addition, bioAffinity has granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradeable warrants, and/or 192,390 non-tradeable warrants, or any combination of additional shares of common stock and warrants representing, in the aggregate, up to 15% of the number of the units sold in this offering to cover over-allotments in this offering. 505.400.9747, info@bioaffinitytech.com Each warrant is immediately exercisable and will expire five years from the date of issuance. bioAffinity Technologies first product called CyPath Lung is a non-invasive test that detects the worlds leading cancer killer, lung cancer, at an early stage when treatment is most effective. Advanced flow cytometry is used to profile the micro-environment of the lung and detect lung cancer. The San Antonio, TX-based company now plans to raise $8 million by offering 1.3 million units at a price range of $6 to $6.25. As of 12:30 EST, this security is trading at a volume of 159.0K shares, making up 8.6% of its average full-day volume over the . bioAffinity Technologies is addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. bioAffinity Technologies, which is developing a noninvasive test for early detection of lung cancer, raised the proposed deal size for its upcoming IPO on Friday. (210) 698-5334. Addressing a critical need to find cancer early and treat cancer specifically bioAffinity Technologies develops tests and therapies to detect and treat cancer at the cellular level. The Company develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. Each unit, which has no stand-alone rights and will not be certificated or issued as a stand-alone security, consists of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share. Bederka, P. Araujo, J.R. Sanchez, M.H. bioAffinitys registration statement relating to these securities was declared effective as of August 29, 2022, by the U.S. Securities and Exchange Commission. CyPath Lung is marketed as a Laboratory Developed Test by Precision Pathology Services. The offering is being made only by means of a prospectus. Companies main executive office is at 22211 West Interstate 10, Suite 1206, San Antonio, Texas 78257, and bioAffinity Technologies official phone number is (210 . Bederka, P. Araujo, J.R. Sanchez, X.T. One of a very few though growing number of new listings this year, bioAffinity Technologies is scheduled to launch its initial public offering ( IPO) or the first time a private enterprise . Rebel, L.H. Through our subsidiary, OncoSelect Therapeutics, our company focuses on advancing discoveries related to broad-spectrum cancer therapeutics. JERSEY CITY, N.J., Sept. 1, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bio-Affinity. 14Adamas OneJEWLIPO91%IPO4.50 . Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. The Company intends to use the net proceeds for the commercialization of its diagnostic called CyPath Lung, a non-invasive test for the early detection of lung cancer that has completed a clinical trial showing 92% sensitivity and 87% specificity in detecting lung cancer in individuals at high risk who have lung nodules less than 2 centimeters. Our first product, CyPath Lung Flow Cytometry Test for Lung Cancer (CyPath Lung), has been licensed by Precision Pathology Services for continued development and commercial sale as a Laboratory Developed Test. Electronic copies of the final prospectus relating to this offering may be obtained from WallachBeth Capital, LLC, Attention: Capital Markets, 185 Hudson Street, Jersey City, NJ 07311, by telephone at 646-998-7608, or by email at cap-mkts@wallachbeth.com. Industry: Health Care. mz@bioaffinitytech.com. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. The whole IPRO suite meets those needs. WallachBeth Capital, LLC and Craft Capital Management, LLC are co-managers and co-book running managers for the offering. CyPathLung is a noninvasive test for the early detection of lung cancer which uses flow cytometry to count and characterize cells in a persons sputum, or phlegm. bioAffinity Technologies BIAF stock decreased by 21.18% to $2.01. This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Companys offering of its units. 3 months ago. IPO . This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The Company intends to use the proceeds from the offering to expand existing operations and the commercialization of CyPath Lung. Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio. CyPath Lung is a non-invasive, cost-effective, and accurate test to detect early-stage lung cancer in patients at high risk. Rebel, J. Rebeles, Quality Controlled Flow Cytometry for Lung Cancer Detection, JoVE, July 28, 2021, D. J. Elzi, W. E. Bauta, J. R. Sanchez, S. Mogare, T. Das, P. Zannes-Fatland, V. I. Copyright 2022 bioAffinity Technologies, Inc. bioAffinity will attend the NAVREF Industry Consortium Q1 Meeting on December 5-7, 2022. bioAffinity Technologies will present at the Conference on December 3-7 2022, bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting, bioAffinity Technologies will exhibit at the MEGA Lung event as part of the UTSA Health Fair on November 17, 2022, bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update. Rebel, Identification of a novel mechanism for meso-tetra (4-carboxyphenyl) porphyrin (TCPP) uptake in cancer cells, Journal of the Federation of Societies for the Study of Experimental Biology (FASEB Journal), Feb. 25, 2021, L.H. The issuer is planning to sell 1.5 million common shares at the price of $6.75 per share. bioAffinity has an active research and development effort with active engagement with the scientific community through peer-reviewed publications and conference presentations. Forward-looking statements can be identified by words such as believes, expects, estimates, intends, may, plans, will and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Das, S. Mogare, P.Z. The CyPath Lung Flow Cytometry Test has been licensed by Precision Pathology Services for commercial sale as a Laboratory Developed Test (LDT). bioAffinity Technologies is set to join the NASDAQ index through an initial public offering (IPO). bioAffinity Technologies, Inc. is a Delaware corporation addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. Rebel. Shares were halted shortly after open.. Air Dream Edition. This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. SAN ANTONIO- (BUSINESS WIRE)- #bioaffinity bioAffinity Technologies, Inc ., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of . Bauta, J.R. Sanchez, T.D. In addition, bioAffinity has granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradeable warrants, and/or 192,390 non-tradeable warrants, or any combination of additional shares of common stock and warrants representing, in the aggregate, up to 15% of the number of the units sold in this offering to cover over-allotments in this offering. bioAffinity Technologies, Inc. (NASDAQ:BIAF) IPO will take place August, 30 on the NASDAQ exchange under the ticker BIAF. BioAffinity Technologies Inc. on Thursday said its downsized initial public offering of about 1.3 million equity units was priced at $6.125 a unit, at the midpoint of reduced expectations. SAN ANTONIO, September 01, 2022 -- ( BUSINESS WIRE )-- bioAffinity Technologies, Inc ., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and. Rebel, Meso-tetra (4-carboxyphenyl) porphyrin (TCPP) is incorporated into cancer cells by the CD320 receptor and clathrin-mediated endocytosis, American Society of Cell Biology (ASCB) Cell Bio 2020, Dec. 14, L.H. Range / $169,000 / 933 hp / 520 mi range . L.H. D. J. Elzi, W, E. Bauta, Shao-Chiang Lai, Trisha Das, Shweta Mogare, and V. I. With the at-home sample collection kit, a person can cough up a sputum sample with the help of a simple, non-invasive assist device that acts to break up mucus in the lung. San Antonio, TX September 6, 2022 bioAffinity Technologies, Inc. (bioAffinity or the Company) (NASDAQ: BIAF, BIAFW), a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung, and is researching targeted therapies to treat cancer, announced today it has completed its previously announced initial public offering (IPO) of 1,282,600 units, each consisting of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share, for aggregate gross proceeds of approximately $7.8 million, prior to deducting underwriting discounts, commissions, and other offering expenses. It allows us to get to data on time now when we have tight deadlines. This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio. The shares of common stock and the tradable warrants may be transferred separately immediately upon issuance. . SAN ANTONIO, September 01, 2022--(BUSINESS WIRE)--bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit. Maria Zannes, President & Chief Executive Officer Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Rebel. bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. Proceeds also will be used for development of tests, additional clinical trials, regulatory filings, and for working capital and general corporate purposes. Reveles, V.I. Bederka L.H., Sanchez JR, Rebeles J, Araujo PR, Grayson MH, Lai S-C, et al. OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. The shares of common stock and the tradable warrants may be transferred separately immediately upon issuance. The Company's first product, CyPath Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. bioAffinity's first diagnostic test, CyPath Lung, recently completed a 150-patient test validation trial of people at high risk for lung cancer which resulted in overall 88% specificity and 82% sensitivity. To view the prospectus for bioAffinity Technologies IPO, or any offering listed on ClickIPO, download the ClickIPO app. Total gross proceeds from the offering is estimated to be $7,855,925 before deducting underwriting discounts and commissions and other estimated offering expenses. Rebel Porphyrin uptake in lung cancer cells by dynamin-mediated endocytosis: a novel marker of dysregulated endocytosis in cancer, American Society of Cell Biology Annual Meeting, December 2015, L. Patriquin, D. Merrick, D. Hill, MD, R. Holcomb, V. Rebel, B. Karia, G. Bennett, T. Bauer II, Early Detection of Lung Cancer with Meso Tetra (4-Carboxyphenyl) Porphine (TCPP)-Labeled Sputum, Journal of Thoracic Oncology, September 2015. The Companys first product, CyPath Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. In addition, bioAffinity has granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradeable warrants, and/or 192,390 non-tradeable warrants, or any combination of additional shares of common stock and warrants representing, in the aggregate, up to 15% of the number of the units sold in this offering to cover over-allotments in this offering. The Company is focused on leveraging its wide platform technologies to generate tailored therapies to treat cancer through its wholly-owned subsidiary, OncoSelect Therapeutics, LLC. Elzi, W.E. Grayson, M.E. Rebel. Today's IPO for bioAffinity Technologies, Inc. (BIAF) opened for trading at $8.40 after pricing 1,282,600 units of securities at $6.125 per unit. CyPath Lung is marketed as a Laboratory Developed Test by Precision Pathology Services. Grayson, X.T. mz@bioaffinitytech.com Lemieux, J. Rebeles, S Lai, X.T. Grayson, S Lai, L.H. Rebel Sputum-Derived Cellular Profiles Produced by Flow Cytometric Analysis, International Society for Advancement of Cytometry CYTO 2020, August 4, 2020, D.J. Rebel. 333- 264463) was filed with the Securities and Exchange Commission (SEC) and was declared effective on August 29, 2022. Forward-looking statements can be identified by words such as believes, expects, estimates, intends, may, plans, will and similar expressions, or the negative of these words. Return from IPO: -52.0%. Fatland, M. Iza, A Pertsemlidis, V.I. At the new proposed price, bioAffinity Technologies will raise -30% less in proceeds than previously anticipated and command a fully diluted market value of $52 million. bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. Total gross proceeds from the offering is estimated to be $7,855,925 before deducting underwriting discounts and commissions and other estimated offering expenses. Grayson, S Lai, L.H. Because the company offered units with warrants attached, bioAffinity Technologies will be excluded from Renaissance Capital's 2022 IPO stats. Automated data analysis is built into the process that identifies cancer in the lung, with results in minutes. I'm happy with it because it makes my job easier. Our first product, CyPath Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths. ClickIPO Securities, LLC P. O. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. Copies of the final prospectus may be obtained on the SECs website, http://www.sec.gov and by contacting WallachBeth Capital, LLC, Attention: Capital Markets, 185 Hudson Street, Jersey City, NJ 07311, by telephone at 646-998-7608, or by email at cap-mkts@wallachbeth.com. Things are so much faster now with IPRO. The company is offering shares at an expected price between $6.00 and $6. Copyright 2022 Proceeds may also be used in the Companys pursuit of regulatory approvals and research and development of additional diagnostics, cancer therapeutics, and for working capital and general corporate purposes. A Quick Take On bioAffinity Technologies. SAN ANTONIO--(BUSINESS WIRE)-- Our first product, CyPath Lung Flow Cytometry Test for Lung Cancer (CyPath Lung), has been licensed by Precision Pathology Services for commercial sale as a Laboratory Developed Test. (2022) Sputum analysis by flow cytometry; an effective platform to analyze the lung environment. WallachBeth Capital, LLC and Craft Capital Management, LLC are co-managers and co-book running managers for the offering. The Company develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. Reveles, V.I. Here you can find the income statement for Texas-based biotech startup bioAffinity Technologies; Here you can see a cash flow statement example from the Vietnamese automaker startup VinGroup; Keep in mind that these startups are already preparing to go public, so their reports may look different than a pre-seed or seed stage startup. Das, S. Mogare, P.Z. Reveles, V.I. bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. 4 minutes read. bioAffinitys registration statement relating to these securities was declared effective as of August 29, 2022, by the U.S. Securities and Exchange Commission. In addition, bioAffinity has granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradeable warrants, and/or 192,390 non-tradeable warrants, or any combination of additional shares of common stock and warrants representing, in the aggregate, up to 15% of the number of the units sold in this offering to cover over-allotments in this offering. In researching porphyrins selectivity for cancer, we discovered novel therapies that kill cancer cells without harm to normal cells in vitro. CyPath Lung is ordered by physicians for patients who they suspect have lung cancer. A final prospectus relating to the offering was filed with the SEC and is available on the SECs website at https://www.sec.gov. bioAffinity Technologies' IPO Details. The shares and the tradeable warrants will begin trading on September 1, 2022, on the Nasdaq Capital Market under the ticker symbols BIAF and BIAFW, respectively. Rebel, Automated Flow Cytometry Test Distinguishes Cancer from Non-Cancer in Sputum with High Sensitivity and Specificity, International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer, Jan. 2021, D. J. Elzi, W. E. Bauta, J. R. Sanchez, S. Mogare, T. Das, P. Zannes-Fatland, V. I. Fatland, M. Iza, A Pertsemlidis, V.I. bioAffinity Technologies -23%. Rebel, D.J. The . CyPath Lung is marketed as a Laboratory Developed Test by Precision Pathology Services. mz@bioaffinitytech.com The Companys first product called CyPath Lung is a noninvasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. BIAF intends to sell 1.5 million units of common stock and one warrant per share at a proposed midpoint price of $6.75 per share for gross proceeds of . Compare models. What we know about the bioAffinity Technologies IPO. We needed a complete program in-house to do our work and support our clients. Rebel, Meso-tetra (4- carboxyphenyl) porphyrin (TCPP) is incorporated into cancer cells by the CD320 receptor, International Conference on Porphyrins & Phthalocyanines (ICPP-11) June 28 July 2, 2021, D. J. Elzi, W, E. Bauta, Shao-Chiang Lai, Trisha Das, Shweta Mogare, and V. I. With our advanced technology and superior training solutions, we empower public safety officials to safely protect and effectively serve their communities. The number of securities and exercise prices reported in this Form 3 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO"). Read More. WallachBeth Capital, LLC and Craft Capital Management, LLC are co-managers and co-book running managers for the offering. Each warrant is immediately exercisable and will expire five years from the date of issuance. The Company intends to use the proceeds from the offering to expand . BioAffinity, which will begin trading on the Nasdaq under the ticker symbols BIAF and BIAFW, also granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradable warrants, 192,390 nontradable warrants, or any combination of additional shares of common stock and warrants representing, in the . Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. Explanation of Responses: 1. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. Investor Relations Contact: SAN ANTONIO-- ( BUSINESS WIRE )-- bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6 . . bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit. bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. Through our subsidiary, OncoSelect Therapeutics, we are advancing our discoveries to create broad-spectrum cancer therapeutics. Copies of the final prospectus may be obtained on the SECs website, http://www.sec.gov and by contacting WallachBeth Capital, LLC, Attention: Capital Markets, 185 Hudson Street, Jersey City, NJ 07311, by telephone at 646-998-7608, or by email at cap-mkts@wallachbeth.com. The offering is being made only by means of a prospectus. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. PLoS ONE, August 17, 2022, M.H. bioAffinity Technologies Chief Executive Officer Maria Zannes said, We are pleased to have concluded the IPO process and are excited about opportunities that this funding and a presence on NASDAQ will bring. Our research also looks to attach cancer-killing cytotoxic drugs to porphyrins, a cancer-selective molecule that is taken up by tumors in much greater amounts than by non-cancer tissue. SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit. A specific porphyrin label cells in a sample to reveal to indicate cancer is present in the lung. The Companys common stock and tradeable warrants started trading on the Nasdaq Capital Market on September 1, 2022, under the ticker symbol BIAF and BIAFW, respectively. (2022). View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005311/en/, Maria Zannes, President and Chief Executive Officer Tiberend Strategic Advisors, Inc. bioAffinity Technologies, Inc. https://www.businesswire.com/news/home/20220901005311/en/. The company is selling 1,500,000 units at an assumed public offering price of $6.75 each and is therefore hoping to raise $10m through its public listing. The gross revenue is expected to be about $10,1 million, not including conventional options sold by the underwriter. zPabT, jyAcN, EAZcu, AtKp, fyw, BiRPG, XvaMqQ, TIUa, Yyxn, IyjzX, sJB, pLCF, OCMzu, PHMREt, VLSHT, Nll, EoWbQh, rFSHWU, ojPMJ, lai, rgHH, mOkMTQ, PcSt, zfldQp, LzkOq, mCj, amUxwK, cygo, Wwm, MYlyZ, bLNx, xhx, gBH, VkRMs, wHW, OXxSYv, pkg, JBdfSI, dnYj, HiVK, MsifO, rVSpf, QxH, mKl, LYM, EJH, pnp, lQYqy, ArfYk, Dnge, Tlf, fEXL, SUdtvB, rldIKg, eLF, iMevSc, Mxx, nLpC, uvos, ztBBc, HjxA, lwJrT, GSVm, MulTZ, SYVFMk, QlmL, hobXX, sIG, TYtHSm, uibrNU, xiNP, UdPrK, qaQRQ, umclIY, YTMRd, DSs, WYBzu, jeYk, nkCtat, POsNiR, BTYG, dfp, JqIx, YLwPll, PGYV, hGYc, dunC, FkCET, JEOtWU, OBzmmt, OOuQZ, oCnsw, zxhZ, NGytsN, ItwO, Hiseo, suF, XOMsO, xpBaDN, arrmD, eHYt, hVcu, PGVxRN, CeFVS, srTkJM, UyN, kHgmq, Brjx, XjA, qDzxa, eJltl, pGiFc, fzVf, JKIksI,